|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$82,330,696 |
|
|
Indirect Value
|
$12,970,625,176 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,052,955,872 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
36
|
6
|
Stock
price went up :
|
15
|
6
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
Percentage
Gain/Loss : |
-24.3%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 13 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-01-04 |
4 |
S |
$13.14 |
$13,550 |
I/I |
(1,031) |
89,722 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-01-03 |
4 |
S |
$13.29 |
$13,159 |
I/I |
(990) |
90,753 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-09 |
4 |
B |
$4.05 |
$18,152 |
I/I |
4,482 |
91,239 |
2.17 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-08 |
4 |
B |
$7.21 |
$20,762 |
I/I |
2,879 |
91,713 |
1.5 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-01-02 |
4 |
S |
$12.94 |
$38,144 |
I/I |
(2,947) |
91,743 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-09 |
4/A |
B |
$4.05 |
$18,152 |
I/I |
4,482 |
91,780 |
2.17 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-10 |
4 |
B |
$4.03 |
$335 |
I/I |
83 |
91,863 |
2.17 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-12 |
4 |
B |
$5.58 |
$148,020 |
I/I |
26,535 |
92,120 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2008-06-06 |
4 |
B |
$20.01 |
$103,080 |
I/I |
5,102 |
92,236 |
2.25 |
- |
|
BCRX |
Biocryst Pharmaceuticals ... |
10% Owner |
|
2009-05-28 |
4 |
S |
$4.45 |
$77,618 |
I/I |
(17,302) |
92,414 |
0 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-09 |
4 |
B |
$6.96 |
$6,250 |
I/I |
898 |
92,611 |
1.5 |
- |
|
RDEA |
Ardea Biosciences Inc |
Director |
|
2011-01-20 |
4 |
B |
$26.00 |
$255,190 |
I/I |
9,815 |
93,282 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-10-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,542) |
94,049 |
|
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-10 |
4 |
B |
$7.47 |
$12,451 |
I/I |
1,667 |
94,278 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-11 |
4 |
B |
$4.03 |
$9,855 |
I/I |
2,446 |
94,309 |
2.17 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2008-06-09 |
4 |
B |
$19.61 |
$41,071 |
I/I |
2,089 |
94,325 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-12 |
4 |
S |
$12.25 |
$61 |
I/I |
(5) |
94,691 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-11 |
4 |
S |
$12.25 |
$3,247 |
I/I |
(265) |
94,696 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-10 |
4 |
S |
$12.36 |
$7,443 |
I/I |
(602) |
94,961 |
0 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-11 |
4 |
B |
$7.47 |
$5,919 |
I/I |
792 |
95,070 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-14 |
4 |
B |
$4.05 |
$3,443 |
I/I |
850 |
95,159 |
2.17 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-07 |
4 |
S |
$12.25 |
$9,534 |
I/I |
(778) |
95,563 |
0 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2008-05-07 |
4 |
A |
$0.00 |
$0 |
I/I |
42,089 |
95,646 |
0 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2008-12-19 |
4 |
B |
$11.14 |
$44,449 |
I/I |
3,990 |
95,646 |
1.5 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2005-07-14 |
4 |
B |
$3.50 |
$29,288 |
I/I |
8,368 |
95,772 |
1.5 |
- |
|
1397 Records found
|
|
Page 13 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|